Form 4 for IMDX Insight Molecular Diagnostics Inc.

Accepted 2023-04-05 00:00:00 ET · period of report 2023-04-03 · accession 0000919574-23-002420 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2023-04-05	2023-04-03	IMDX	BROADWOOD PARTNERS, L.P.	10%	P - Purchase	—	0	50.18M	New	—
	2023-04-05	2023-04-03	IMDX	BROADWOOD PARTNERS, L.P.	10%	P - Purchase	$0.3	+26.83M	50.18M	+115%	+$8.05M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, no par value	2023-04-03	P	A	0	$0.00	50,181,335	I	—	—
2	Common	Common Stock, no par value	2023-04-03	P	A	26,827,638	$0.3	50,181,335	D Footnote	—	—	(F3) On April 3, 2023, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 26,827,638 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $8,093,361.84, or $0.30168 per Common Share. (F1) The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. ("Broadwood Capital") as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.